Monte Rosa Therapeutics Will Present Preclinical Data At Digestive Disease Week 2024. Data Showed That MRT-6160-mediated Degradation Of VAV1 Inhibited Disease Progression In A T-Cell Transfer Murine Model Of Colitis
VAV1 is a key signaling protein downstream of both the T-and B-cell receptors and its degradation has potential to treat multiple T-cell and/or Th17 mediated autoimmune and inflammatory diseases, including ulcerative colitis (UC).